Xencor Inc Files Patent for Bispecific Antibody to Treat GPC3-Associated Cancers

According to GlobalData’s company profile on Xencor, Personalized cancer vaccines was a key innovation area identified from patents. Xencor‘s grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Bispecific antibody for treating gpc3-associated cancers

A recently granted patent (Publication Number: US11859012B2) discloses a bispecific antibody designed to bind to human CD3 and human GPC3. The antibody is composed of three monomers with specific amino acid sequences outlined in the patent claims. Additionally, the patent covers a nucleic acid composition containing the genetic information for each monomer, as well as an expression vector composition and a host cell for producing the bispecific antibody.

Furthermore, the patent details a method for manufacturing the bispecific antibody by culturing the host cell containing the expression vector composition under specific conditions to express and recover the antibody. This innovative approach to creating a bispecific antibody targeting human CD3 and human GPC3 showcases advancements in the field of biotechnology and holds promise for potential therapeutic applications in the future.

To know more about GlobalData’s detailed insights on Xencor, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies